Navalit (Doxylamine Hydrogen Succinate, Pyridoxine Hydrochloride)

Doxylamine hydrogen succinate, the active ingredient in Navalit, is a first‑generation antihistamine presented as an oral tablet for oral use. It is combined with pyridoxine hydrochloride to treat nausea and vomiting of pregnancy, commonly known as morning sickness and provides symptomatic relief for many pregnant women.

GNH USA supplies Navalit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customers benefit from reliable logistics and comprehensive documentation for import clearance.

Navalit combines a first‑generation antihistamine with vitamin B6 and is used to manage nausea‑related conditions. - Nausea and vomiting of pregnancy (morning sickness): reduces frequency and severity of symptoms in pregnant women. - Antiemesis in non‑pregnant patients: provides relief from nausea associated with gastrointestinal disorders or medication side effects. - Adjunct therapy with other anti‑emetics: enhances overall control of vomiting when used together with additional agents.

Common and serious adverse reactions have been reported with Navalit, reflecting the pharmacology of its components.

Common Side Effects: - Drowsiness - Dry mouth - Constipation - Blurred vision - Dizziness - Headache

Serious or Rare Side Effects: - Anaphylactic reaction - Stevens‑Johnson syndrome - Hepatic dysfunction - Seizures - Cardiac arrhythmia - Severe respiratory depression

When prescribing Navalit, several precautions should be observed to ensure safe use. - Pregnancy use: only when benefit outweighs potential risk to the fetus. - Sedation risk: avoid operating machinery or driving until individual response is known. - Concomitant CNS depressants: use caution with alcohol, opioids, or other sedatives. - Hepatic impairment: dose adjustment may be required in patients with liver disease. - Anticholinergic burden: monitor for exacerbated dry mouth or urinary retention when combined with other anticholinergic drugs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Navalit may interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other sedating antihistamines: additive CNS depression. - Alcohol: enhances drowsiness and respiratory depression. - Opioid analgesics: increased sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen dry mouth and urinary retention. - CYP2D6 substrates (e.g., codeine, tramadol): potential alteration of metabolism. - Antidepressants (SSRIs, SNRIs): monitor for increased nausea control but possible serotonin syndrome when combined with other serotonergic agents.